PRIME’s technology for the development of novel veterinary vaccines
Boehringer Ingelheim and Biotech Startup enter a strategic collaboration
pixabay.com
ORFV platform
ORFV belongs to the family of poxviridae and possesses an excellent safety profile, stable expression of multiple transgenes simultaneously and is well suited for the possibility of multiple dose immunizations. Prior to the collaboration agreement, the platform was developed at the University of Tuebingen, and showed to be effective in various host animals against different infectious diseases. “After so many years of research and development on our platform, we are proud to receive the commitment to and trust in our technology from Boehringer Ingelheim as one of the world’s leading pharmaceutical companies in the animal health market. With this strong partner, we are excited to advance our technology and to enhance our contribution to improving animal health,” says Dr. Ralf Amann, CEO of PRIME.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.